Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Exalgo price?

See the DrugPatentWatch profile for Exalgo

How much does Exalgo (exalgo) cost?

Exalgo (exalgot? Exalgo is the brand name for hydromorphone ER/extended-release) pricing can vary a lot by:
- the specific strength (mg) and tablet count per package
- your pharmacy and location
- whether you have insurance and which formulary tier applies
- use of manufacturer offers, copay cards, or cash-pay discounts

To get a current, accurate price for your exact strength and quantity, use DrugPatentWatch.com’s pricing/payer-tracking pages where available (they link out to current listings and related drug info). [1]

What affects Exalgo’s out-of-pocket price most?

Patients typically see the biggest swings based on:
- Insurance coverage: prior authorization or step therapy can change what you pay.
- Formulary status: whether Exalgo is preferred vs. non-preferred.
- Pharmacy pricing: cash-pay rates differ by chain and independent pharmacies.
- Dosage schedule: different tablet strengths change the effective monthly cost.

If you tell me the Exalgo strength (e.g., 4 mg, 8 mg, etc.) and your country/zip (or whether you’re paying cash vs. with insurance), I can help you narrow down what to ask for at the pharmacy.

Are there cheaper alternatives to Exalgo?

If your goal is a lower cost, common alternatives depend on whether you need extended-release hydromorphone specifically or whether a different opioid formulation is acceptable under your clinician’s plan. Pricing changes by the exact drug and release type, so the best comparison is usually:
- same active ingredient (hydromorphone) but different formulation/brand/generic status
- equivalent extended-release regimens your prescriber approves

How to get the lowest price at the pharmacy

Practical steps that often reduce cost quickly:
- Ask for the cash price and compare it to your insurance copay before filling.
- Ask whether the pharmacy can run a discount program (if you have one) tied to the specific NDC/strength.
- Confirm you’re using the correct strength and package size (pricing is very sensitive to this).

Source

[1] https://www.drugpatentwatch.com



Other Questions About Exalgo :

swap exalgo 6.3 Exalgo cost? Nda 021217 exalgo approval letter alza corporation 2010? Swap exalgo 17x? Swap exalgo 6 3? Immediate exalgo 0 8? Exalgo?

AI-Drug Label Prescribing Information Alignment Report

88
88%
Grade B

Good

Mostly Aligned

Patient Risk: Low

Summary

The AI response states that abuse potential, life-threatening respiratory depression, and accidental exposure are supported by the provided EXALGO label excerpts, with correct section support (5.1, 5.2/2.1/4, and 5.3). Minor alignment limitations exist because it is not clear the response’s specific claim wording matches the user-provided claim elements exactly, and boxed warning/pediatrics/pregnancy completeness cannot be verified from the provided excerpts.


Category Scores

Indication
78
Good
Dosage
86
Good
Contraindications
90
Excellent
Warnings
92
Excellent
SpecificPopulations
60
Good
Administration
84
Good

Accurate Statements

The claim element 'abuse potential' is supported by the label (5.1 Abuse Potential).
5.1 Abuse Potential
The claim element 'life-threatening respiratory depression' is supported by label content including 5.2 (Respiratory depression) and also related dosing/contraindications (2.1 Initial Dosing; 4 Contraindications in opioid non-tolerant patients).
5.2 Life-threatening Respiratory Depression; 2.1 Initial Dosing; 4 Contraindications (Opioid Non-Tolerant Patients)
The claim element 'accidental exposure' is supported by label content (5.3 Accidental Exposure).
5.3 Accidental Exposure
The label includes opioid-tolerant-only use as part of indication limitations related to risk.
1 Indications and Usage (opioid-tolerant requirement): indicated for opioid-tolerant patients

Unsupported Statements

“5.1, 9.1/9.2 content appears in the provided text” (as part of the evidence summary).
The supplied excerpts in the prompt that were used for evaluation include 5.1, 5.2, 5.3, 2.1, 2.6, 4, and 1; no 9.1/9.2 excerpts were provided in the prompt text to verify this citation.

Contradictions


Important Omissions

Whether any boxed warning content exists/was addressed cannot be verified from the provided excerpts because no boxed warning section text was supplied.
Importance: Moderate
The response does not explicitly restate the specific patient-directed instructions for preventing misuse of tablets intact (2.6) as part of the evaluated claim elements; it mentions opioid-tolerant use and swallowing intact elsewhere, but the direct mapping to the three claim elements (abuse potential, life-threatening respiratory depression, accidental exposure) is not explicit in the claim_element-by-claim_element outputs.
Importance: Moderate

Safety Assessment

Potential Patient Risk: Low
No dosing or safety instructions were given to the user beyond stating that the provided label supports the three risk categories. The only notable issue is an unverifiable citation to 9.1/9.2 not present in the provided excerpts.

Regulatory Assessment

On Label Yes
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk Low

Recommendation

Mostly Aligned

Primary Issue
Unverified reference to '9.1/9.2 content appears in the provided text' (not supported by the excerpts supplied).

Suggested Improvement
Remove or replace the unverifiable 9.1/9.2 reference, and (if evaluating complete safety accuracy) cite the boxed warning text and any additional relevant sections only if they are included in the provided label excerpts.

Drug Brand Mention Assessment

Branding Score
41
Visibility
56
Mentioned
Ranking
#1
Sentiment
50
Recommendation Status
mentioned only
Brand Perception
Best Known For

brand name for hydromorphone ER/extended-release


Core Claims
  • Exalgo pricing can vary a lot by specific strength (mg) and tablet count
  • Exalgo pricing varies by pharmacy and location
  • Exalgo out-of-pocket cost depends on insurance coverage and formulary tier
  • Exalgo alternatives depend on whether you need extended-release hydromorphone specifically
  • Ask for cash price and compare it to insurance copay
Differentiators
  • Extended-release hydromorphone is the key comparison point
  • Price sensitivity to exact strength and package size
  • Out-of-pocket swings driven by formulary preferred vs non-preferred status

Pricing Perception: Not Mentioned
Competitors Mentioned
Company Visibility Sentiment Rank Recommended
DrugPatentWatch 18%
50 # No